Oppenheimer upgraded Biomarin Pharmaceutical (TADAWUL:2070) Inc (NASDAQ:BMRN) to "Outperform" from "Perform," citing strong fourth-quarter results and increasing confidence in the company's long-term ...
Oppenheimer upgraded BioMarin (BMRN) to Outperform from Perform with a $98 price target Discover the Best Stocks and Maximize Your Portfolio: ...
Oppenheimer upgraded BioMarin (BMRN) to Outperform from Perform with a $98 price target BioMarin reported strong Q4 results and Oppenheimer ...
Hosted on MSN13m
Does BioMarin (BMRN) Have the Potential to Rally 40.54% as Wall Street Analysts Expect?Shares of BioMarin Pharmaceutical (BMRN) have gained 10.6% over the past four weeks to close the last trading session at $68.25, but there could still be a solid upside left in the stock if short-term ...
Hosted on MSN23h
What To Expect From Myriad Genetics’s (MYGN) Q4 EarningsGenetic testing company Myriad Genetics (NASDAQ:MYGN) will be reporting results tomorrow after market hours. Here’s what you ...
Beqvez was Pfizer's first gene therapy, stemming from an alliance with Spark Therapeutics (now part of Roche) more than a ...
Beqvez was Pfizer's first gene therapy, stemming from an alliance with Spark Therapeutics (now part of Roche) more than a ...
Tracks the performance of pharmaceutical companies in India, comprising leading pharmaceutical stocks listed on the National Stock Exchange (NSE), reflecting trends in the pharmaceutical sector.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback